<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02290470</url>
  </required_header>
  <id_info>
    <org_study_id>Gineolanzapina</org_study_id>
    <nct_id>NCT02290470</nct_id>
  </id_info>
  <brief_title>Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel</brief_title>
  <official_title>Olanzapine for the Prevention of Delayed Nausea and Vomiting in Patients With Gynecologic Cancers Receiving Carboplatin and Paclitaxel-based Chemotherapy and Guideline-directed Prophylactic Anti-emetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, pilot study explores the activity of olanzapine with or without delayed&#xD;
      dexamethasone for the prevention of delayed nausea and vomiting in women with gynecologic&#xD;
      cancer receiving the combination of carboplatin and paclitaxel. Women treated with this&#xD;
      regimen are particularly susceptible to chemotherapy-induced nausea and vomiting. Given&#xD;
      anti-emetic prophylaxis with olanzapine may increase the control of delayed symptoms in women&#xD;
      receiving carboplatin and paclitaxel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess if the use of olanzapine can improve control of&#xD;
      delayed nausea and vomiting in women receiving the combination of carboplatin and paclitaxel&#xD;
      for a gynaecologic cancer. Patients are randomized to one of three treatment arms. Please see&#xD;
      the &quot;Arms and Intervention&quot; sections for more detailed information. The primary objective is&#xD;
      to determine in each treatment group the proportion of patients achieving Complete Protection&#xD;
      (CP; no vomiting, no rescue anti-emetics, and no more than mild nausea) during the delayed&#xD;
      phase (days 2-5 post-chemotherapy) in the first chemotherapy cycle. The secondary objectives&#xD;
      are:&#xD;
&#xD;
        1. To determine the proportion of patients achieving Complete Response (CR; no vomiting,&#xD;
           and no rescue anti-emetics) during the acute (day 1 post-chemotherapy), delayed, and&#xD;
           overall (days 1-5 post-chemotherapy) periods.&#xD;
&#xD;
        2. To determine the incidences of potential toxicities ascribed to olanzapine.&#xD;
&#xD;
        3. To assess the impact of nausea and vomiting on daily life activities in each treatment&#xD;
           group.&#xD;
&#xD;
      Protocol treatment is to begin ≤14 days of registration. Patients will receive treatment on&#xD;
      Days 1-3. Patients will be permitted to take rescue therapy of the treating investigator's&#xD;
      choice based on the clinical circumstances. After completing treatment, patients will be&#xD;
      monitored for side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Protection</measure>
    <time_frame>days 2-5 post-chemotherapy</time_frame>
    <description>Proportion of patients achieving delayed Complete Protection, defined as no vomiting, no rescue anti-emetics, and no more than mild nausea measured by the Nausea and Vomiting Daily Diary/Questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nausea scores</measure>
    <time_frame>up to 5 days</time_frame>
    <description>• Nausea scores measured by the Nausea and Vomiting Daily Diary/Questionnaire.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of patients achieving Complete Response</measure>
    <time_frame>up to 5 days</time_frame>
    <description>• Proportion of patients achieving Complete Response, defined as no emetic episodes and no use of rescue anti-emetics measured by the Nausea and Vomiting Daily Diary/Questionnaire.</description>
  </other_outcome>
  <other_outcome>
    <measure>Impact of nausea and vomiting on daily life activities</measure>
    <time_frame>day 1 (pre-chemotherapy) and day 6 (post-chemotherapy)</time_frame>
    <description>• Impact of nausea and vomiting on daily life activities as measured by the Functional Living Index-Emesis Questionnaire.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of potential toxicities related to olanzapine</measure>
    <time_frame>up to 5 days</time_frame>
    <description>• Incidence of potential toxicities related to olanzapine as measured by the Nausea and Vomiting Daily Diary/Questionnaire. [Time frame: ] [Designated as safety issue: Yes]</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of rescue anti-emetics</measure>
    <time_frame>up to 5 days</time_frame>
    <description>• Frequency of rescue anti-emetics measured by the Nausea and Vomiting Daily Diary/Questionnaire.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>olanzapine Days 1-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olanzapine + Chemotherapy + Antiemetic treatment&#xD;
Patients will receive the chemotherapy drugs carboplatin and paclitaxel as well as the following anti-nausea/vomiting drugs:&#xD;
Palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus&#xD;
Dexamethasone (16 mg intravenously on the day of chemotherapy), plus&#xD;
Olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3 post chemotherapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olanzapine+Dexamethasone d 1-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olanzapine + Chemotherapy + Antiemetic treatment&#xD;
Patients will receive the chemotherapy drugs carboplatin and paclitaxel as well as the following anti-nausea/vomiting drugs:&#xD;
Palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus&#xD;
Dexamethasone (16 mg intravenously on the day of chemotherapy and 4 mg orally days 2, 3 post chemotherapy), plus&#xD;
Olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3 post chemotherapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexamethasone days 1-3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone + Chemotherapy + Antiemetic treatment&#xD;
Patients will receive the chemotherapy drugs carboplatin and paclitaxel as well as usual anti-nausea/vomiting drugs:&#xD;
Palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus&#xD;
Dexamethasone 16 mg intravenously on the day of chemotherapy (day 1), plus&#xD;
Dexamethasone 8 mg orally on days 2 and 3 post chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Drug: Olanzapine 10 mg oral&#xD;
Drug: Chemotherapy (carboplatin and paclitaxel). Patients will receive carboplatin and paclitaxel.&#xD;
Drug: Anti-emetic treatment (palonosetron; plus dexamethasone). Palonosetron (0.25 mg IV) on the day of chemotherapy plus dexamethasone (16 mg IV on the day of chemotherapy and 8 or 4 mg (depending on the experimental arm) oral on days 2 and 3 post-chemotherapy).</description>
    <arm_group_label>dexamethasone days 1-3</arm_group_label>
    <arm_group_label>olanzapine Days 1-3</arm_group_label>
    <arm_group_label>olanzapine+Dexamethasone d 1-3</arm_group_label>
    <other_name>Palonosetron</other_name>
    <other_name>Dexamethasone</other_name>
    <other_name>Carboplatin</other_name>
    <other_name>Paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine</intervention_name>
    <description>all patients enrolled in the study will receive Palonosetron, Dexamethasone, Carboplatin, Paclitaxel and olanzapine On day 1</description>
    <arm_group_label>dexamethasone days 1-3</arm_group_label>
    <arm_group_label>olanzapine Days 1-3</arm_group_label>
    <arm_group_label>olanzapine+Dexamethasone d 1-3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically documented gynaecologic cancer&#xD;
&#xD;
          -  Patients who are chemotherapy naive and scheduled to receive 1-day moderately&#xD;
             emetogenic chemotherapy (carboplatin Area under Curve (AUC) 5 plus paclitaxel).&#xD;
&#xD;
          -  Women, 18 years and older&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2&#xD;
&#xD;
          -  Adequate organ system function, defined as follows:&#xD;
&#xD;
        bone marrow: absolute neutrophil count &gt;=1,500/L, platelets &gt;=100,000/L liver: bilirubin&#xD;
        1.5 x upper limit of normal (ULN); transaminases &lt;=2.5 x ULN kidney: creatinine &lt;=1.5 x ULN&#xD;
&#xD;
        • Able to take oral medications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  history of central nervous system (e.g., brain metastases, seizure disorder)&#xD;
&#xD;
          -  Positive pregnancy test just before registration.&#xD;
&#xD;
          -  treatment with any anti-emetic medication from 24 hours to 5 days after treatment.&#xD;
&#xD;
          -  treatment with another antipsychotic agent such as risperidone, quetiapine, clozapine,&#xD;
             phenothiazine, or butyrophenone for 30 days before or during protocol therapy.&#xD;
&#xD;
          -  concurrent abdominal radiation therapy.&#xD;
&#xD;
          -  concurrent quinolone antibiotic therapy.&#xD;
&#xD;
          -  known hypersensitivity to olanzapine.&#xD;
&#xD;
          -  vomiting and/or significant nausea (&gt;= Common Toxicity Criteria for Adverse Events&#xD;
             (CTCAE) grade 2) within the 24 hours before beginning chemotherapy.&#xD;
&#xD;
          -  another organic cause for nausea or vomiting unrelated to chemotherapy administration.&#xD;
&#xD;
          -  chronic alcoholism (as determined by the investigator).&#xD;
&#xD;
          -  known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial&#xD;
             infarction within the previous 6 months.&#xD;
&#xD;
          -  history of uncontrolled diabetes mellitus.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luigi Celio, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Istituto tumori</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Domenica Lorusso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto tumori</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabriella Saibene, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Tumori</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luigi Celio, MD</last_name>
    <phone>0039 02 2390</phone>
    <phone_ext>2597</phone_ext>
    <email>luigi.celio@istitutotumori.mi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>trialcenter trialcenter</last_name>
    <phone>0039 02 2390</phone>
    <phone_ext>3824</phone_ext>
    <email>trialcenter@istitutotumori.mi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luigi Celio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>May 22, 2014</study_first_submitted>
  <study_first_submitted_qc>November 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <last_update_submitted>November 11, 2014</last_update_submitted>
  <last_update_submitted_qc>November 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nausea</keyword>
  <keyword>Vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

